1,670 Shares in AbbVie Inc. (NYSE:ABBV) Acquired by Blue Capital Inc.

Blue Capital Inc. bought a new position in AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,670 shares of the company's stock, valued at approximately $297,000.

A number of other institutional investors have also modified their holdings of ABBV. Cahill Financial Advisors Inc. bought a new position in AbbVie in the fourth quarter worth approximately $501,000. Captrust Financial Advisors lifted its stake in shares of AbbVie by 5.4% during the 4th quarter. Captrust Financial Advisors now owns 1,295,297 shares of the company's stock worth $230,174,000 after purchasing an additional 66,432 shares during the last quarter. Cary Street Partners Financial LLC bought a new stake in AbbVie during the fourth quarter valued at about $21,859,000. Chapman Financial Group LLC purchased a new position in shares of AbbVie in the 4th quarter worth approximately $515,000. Finally, Brown Advisory Inc. boosted its stake in AbbVie by 2.5% in the fourth quarter. Brown Advisory Inc. now owns 840,660 shares of the company's stock valued at $149,385,000 after acquiring an additional 20,150 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other AbbVie news, SVP Kevin K. Buckbee sold 18,944 shares of the firm's stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $203.41, for a total transaction of $3,853,399.04. Following the completion of the sale, the senior vice president now owns 11,496 shares of the company's stock, valued at $2,338,401.36. This trade represents a 62.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey Ryan Stewart sold 58,832 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $210.08, for a total value of $12,359,426.56. Following the completion of the transaction, the executive vice president now directly owns 53,234 shares in the company, valued at approximately $11,183,398.72. This trade represents a 52.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 113,471 shares of company stock valued at $23,426,451 in the last ninety days. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Price Performance

Shares of AbbVie stock traded down $8.75 during trading hours on Tuesday, reaching $187.32. The stock had a trading volume of 9,383,456 shares, compared to its average volume of 6,092,383. The firm has a market capitalization of $331.37 billion, a PE ratio of 78.05, a PEG ratio of 1.62 and a beta of 0.56. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. The stock's 50 day moving average is $195.64 and its 200 day moving average is $187.27.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The business had revenue of $13.34 billion for the quarter, compared to the consensus estimate of $12.91 billion. During the same period last year, the firm posted $2.31 earnings per share. The company's revenue was up 8.4% compared to the same quarter last year. Equities analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is 279.15%.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ABBV. Cantor Fitzgerald initiated coverage on AbbVie in a report on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price objective for the company. Morgan Stanley increased their price target on AbbVie from $241.00 to $250.00 and gave the company an "overweight" rating in a research note on Monday, April 28th. StockNews.com upgraded shares of AbbVie from a "buy" rating to a "strong-buy" rating in a research note on Monday, April 28th. Truist Financial upped their price target on shares of AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, BMO Capital Markets lifted their price objective on shares of AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a research note on Monday, February 3rd. Six analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have issued a strong buy rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of "Moderate Buy" and an average price target of $211.41.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.